How to Address Uncertainty in Health Economic Discrete-Event Simulation Models: An Illustration for Chronic Obstructive Pulmonary Disease

Background. Evaluation of personalized treatment options requires health economic models that include multiple patient characteristics. Patient-level discrete-event simulation (DES) models are deemed appropriate because of their ability to simulate a variety of characteristics and treatment pathways. However, DES models are scarce in the literature, and details about their methods are often missing. Methods. We describe 4 challenges associated with modeling heterogeneity and structural, stochastic, and parameter uncertainty that can be encountered during the development of DES models. We explain why these are important and how to correctly implement them. To illustrate the impact of the modeling choices discussed, we use (results of) a model for chronic obstructive pulmonary disease (COPD) as a case study. Results. The results from the case study showed that, under a correct implementation of the uncertainty in the model, a hypothetical intervention can be deemed as cost-effective. The consequences of incorrect modeling uncertainty included an increase in the incremental cost-effectiveness ratio ranging from 50% to almost a factor of 14, an extended life expectancy of approximately 1.4 years, and an enormously increased uncertainty around the model outcomes. Thus, modeling uncertainty incorrectly can have substantial implications for decision making. Conclusions. This article provides guidance on the implementation of uncertainty in DES models and improves the transparency of reporting uncertainty methods. The COPD case study illustrates the issues described in the article and helps understanding them better. The model R code shows how the uncertainty was implemented. For readers not familiar with R, the model’s pseudo-code can be used to understand how the model works. By doing this, we can help other developers, who are likely to face similar challenges to those described here.

[1]  K. Rabe,et al.  Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[2]  N. Freemantle,et al.  Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model. , 2006, Diabetes technology & therapeutics.

[3]  I. Buchan,et al.  Calculating when elective abdominal aortic aneurysm repair improves survival for individual patients: development of the Aneurysm Repair Decision Aid and economic evaluation. , 2015, Health technology assessment.

[4]  J Karnon,et al.  Selecting a decision model for economic evaluation: a case study and review , 1998, Health care management science.

[5]  Nicholas R Latimer,et al.  Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  M. Charokopou,et al.  Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system , 2019, Journal of medical economics.

[7]  M. Hoogendoorn,et al.  Broadening the Perspective of Cost-Effectiveness Modeling in Chronic Obstructive Pulmonary Disease: A New Patient-Level Simulation Model Suitable to Evaluate Stratified Medicine. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  Mark Stevenson,et al.  Thrombophilia testing in people with venous thromboembolism: systematic review and cost-effectiveness analysis. , 2009, Health technology assessment.

[9]  Deirdre Mladsi,et al.  The faces of personalized medicine: a framework for understanding its meaning and scope. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  B. Celli,et al.  Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. , 2013, Chest.

[11]  M G Myriam Hunink,et al.  Uncertainty and Patient Heterogeneity in Medical Decision Models , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  S. Chick,et al.  A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.

[13]  Alexandra G. Smith,et al.  A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population–Based Observational Data☆ , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  J. Hay,et al.  Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States , 2018, The Annals of pharmacotherapy.

[15]  S. McGhee,et al.  Cost-effectiveness of a primary care multidisciplinary Risk Assessment and Management Program for patients with diabetes mellitus (RAMP-DM) over lifetime , 2018, Endocrine.

[16]  G. Pledger,et al.  Tiotropium Respimat Inhaler and the Risk of Death in COPD , 2014 .

[17]  K. Boye,et al.  The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  N. Adlard,et al.  When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing–remitting multiple sclerosis , 2018, Journal of medical economics.

[19]  U. Siebert,et al.  Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review , 2017, Applied Health Economics and Health Policy.

[20]  Javier Mar,et al.  Economic Evaluation of an Integrated Health and Social Care Program for Heart Failure Through 2 Different Modeling Techniques , 2018, Health services research and managerial epidemiology.

[21]  Jeffrey D. Miller,et al.  Current challenges in health economic modeling of cancer therapies: a research inquiry. , 2014, American health & drug benefits.

[22]  M. Rutten-van Mölken,et al.  Not Simply More of the Same , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[23]  J. Caro,et al.  Modeling Using Discrete Event Simulation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[24]  Maarten J. IJzerman,et al.  Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. , 2018, Cancer epidemiology.

[25]  Uwe Siebert,et al.  Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  H. Watz,et al.  Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4) , 2015, European Respiratory Journal.

[27]  B. ó Hartaigh,et al.  Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review , 2018, PharmacoEconomics.

[28]  Martin Henriksson,et al.  A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus , 2016, PharmacoEconomics.

[29]  Hendrik Koffijberg,et al.  A systematic review and checklist presenting the main challenges for health economic modeling in personalized medicine: towards implementing patient-level models , 2017, Expert review of pharmacoeconomics & outcomes research.

[30]  G. Pledger,et al.  Tiotropium Respimat inhaler and the risk of death in COPD. , 2013, The New England journal of medicine.

[31]  Mark Stevenson,et al.  NICE DSU Technical Support Document 15: Cost-Effectiveness Modelling Using Patient-Level Simulation , 2014 .

[32]  Jörgen Möller,et al.  Discrete event simulation: the preferred technique for health economic evaluations? , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  D. Sin,et al.  A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[34]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[35]  J. McMurray,et al.  Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms , 2014, Heart.

[36]  M. Atkins,et al.  Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. , 2019, Immunotherapy.

[37]  David Turner,et al.  Barriers and Facilitators to Model Replication Within Health Economics. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[38]  J. Caro,et al.  Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. , 2005, Journal of cardiac failure.

[39]  Javier Mar,et al.  Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model. , 2018, Gaceta sanitaria.

[40]  P. McEwan,et al.  Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK , 2007 .

[41]  M. Atkins,et al.  Sequential treatment approaches in  the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. , 2018, Immunotherapy.

[42]  James E. Stahl,et al.  Pharmacoeconomics 2008; 26 (2): 131-148 , 2012 .

[43]  H. Lemij,et al.  Surveillance for ocular hypertension: an evidence synthesis and economic evaluation. , 2012, Health technology assessment.

[44]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty: a Report of the Ispor-smdm Modeling Good Research Practices Task Force-6 Background to the Task Forcemodel-parameter-estimation-and- Uncertainty-analysis.asp). a Summary of These Articles Was Pre- Sented at a Plenary Session at the Ispor 16th Annual Intern , 2022 .